R&D at Janssen
13, APRIL, 2016
Research & Development at Janssen: innovations which lead to better insights into diseases
As far as Janssen is concerned, working on incremental improvements to healthcare is not enough. We leverage our scientific expertise to transform entire disease categories and make significant contributions to global public health.
In our five priority therapeutic areas, we bring together top scientists and researchers. They pursue the most promising science and promote collaboration to create visionary medicines and healthcare solutions.
With precision medicine, we are working on transforming the study of diseases by investing in best-in-class research capabilities in genomics, biotherapeutics, biomarkers, molecular and companion diagnostics, the microbiome, disease interception and prevention, and vaccine platforms.
We are accessing early-stage breakthrough innovations from the leading innovation hotspots around the world, thereby connecting our in-house expertise with the best available external science.
About Research & Development
At Janssen Research & Development, we are united and energized by one mission – to discover and develop innovative medicines and solutions that transform individuals’ lives and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies of Johnson & Johnson, our strategy is to identify those needs and match them with the best science, internal or external. We deploy our Research & Development expertise and production capacity to market innovative, effective, and safe treatments in five therapeutic areas: cardiovascular and metabolism diseases, immunology, infectious diseases and vaccines, neuroscience en oncology.
We are the world leader in developing biological solutions for the treatment of challenging and complex diseases. Our biotherapeutics organization works to translate scientific discoveries into medicines that will continue to make significant contributions to human health. We have developed a portfolio of more than 50 new and differentiated biological candidate medicines.
We also focus on promising new areas in science, including novel approaches to disease prevention, disease interception and the microbiome – areas which will change the healthcare landscape and the lives of people well into the future.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science and our pursuit of collaborations and partnerships. We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Discovering, developing, and delivering differentiated medicines that address the most serious unmet medical needs of our time requires the best science in the world, whether from within our own walls or through strategic collaborations.
We have formed more than 400 alliances globally and work together with the world’s top minds, ranging from academic institutions and interest groups to companies large and small. These strategic relationships adopt many forms, yet our goal is always the same: to advance scientific research and to deliver innovative solutions that provide value to patients, physicians, and healthcare systems around the world.
Since 2009, our focused strategy has enabled Janssen to introduce 14 new medicines and 35 new indications for existing medicines in major markets. These all provide important new treatment options across a multitude of serious illnesses with a big impact on daily life.
The Janssen Prevention Center is exploring new approaches to disease prevention in major areas of unmet medical need, focusing on chronic non-communicable diseases (NCDs), which are becoming increasingly important in our aging populations. These include illnesses like Alzheimer’s disease, cancer, and heart disease.
The Disease Interception Accelerator is an incubator-like group which addresses the root cause of diseases, intervenes earlier than today’s clinically accepted point of diagnosis, and seeks solutions to stop, reverse, or inhibit the progress of diseases, such as type 1 diabetes, various forms of cancer, and other disease areas of unmet need.
The Janssen Human Microbiome Institute focuses on understanding the microbiome, which is the diverse population of bacteria living in and on the human body, and endeavors in this way to gain more insight into its role in disease. The institute aims to find new therapies for major autoimmune diseases and other conditions for which there are presently no sufficient treatment options.